Source: International Congress 2014 – ILDs 1
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Yao, Y. Cao, Y. R. He, Z. Zeng, Z. A. Liang (Chengdu, China). LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis. Eur Respir J 2014; 44: Suppl. 58, 733

Member's Comments

No comment yet.

Related content which might interest you: Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Lung 18F-FDG uptake correlates with lung function alteration in patients with IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Pirfenidone and BIBF1120 regulate properties of myofibroblasts Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 LATE-BREAKING ABSTRACT: Age-related PINK1 deficiency promotes mitochondria dysfuntion, epithelial injury and fibrosis in the lung Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Transient elastography detection of early liver fibrosis in idiopathic pulmonary fibrosis patients Source: International Congress 2014 – ILDs 2 Year: 2014 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014